Nanomedicines and Nanosimilars—Why a Robust Centralised Regulatory Framework Is Essential to Enhance Patient Safety

Detalles Bibliográficos
Autor principal: Isles, Michael P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8907565/
https://www.ncbi.nlm.nih.gov/pubmed/35280250
http://dx.doi.org/10.3389/fphar.2021.787239

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8907565/
https://www.ncbi.nlm.nih.gov/pubmed/35280250
http://dx.doi.org/10.3389/fphar.2021.787239

Ejemplares similares